地榆升白片治疗改良EOF方案化疗后骨髓抑制的疗效观察

摘要

目的:观察地榆升白片防治晚期胃癌患者化疗后骨髓抑制的疗效及不良反应.方法:初治晚期胃癌患者80例采用表阿霉素+奥沙利铂+5-FU(CIV)方案(即改良EOF方案)化疗,随机分为试验组40例,采取改良EOF方案化疗同时联合地榆升白片治疗;对照组40例,仅采用改良EOF方案化疗,观察化疗期间两组白细胞的变化、粒细胞集落刺激因子(rhC-CSF)使用量及继发感染情况.结果:试验组在化疗期间有10例(25%)Ⅲ度以上白细胞下降,对照组有18例(45%)Ⅲ度以上白细胞下降,两组相比差异有统计学意义(P<0.05),粒细胞集落刺激因子(rhG-CSF)使用量及继发感染率均下降.结论:地榆升白片防治改良EOF方案化疗骨髓抑制疗效好,且安全性高,值得临床推广应用.%Objective: To observe clinical effects and adverse reactions of Diyushengbai tablets on treating myelosuppression in patients receiving chemotherapy of improved EOF regimen. Methods: Eighty cases of advanced gastric cancer were randomly divided into two groups. 40 patients in experimental group were treated by EOF regimen plus Diyushengbai tablets and 40 patients in control group were treated by EOF regimen only. Patients were evaluated by white blood cell count, the dose of rhG-CSF and the secondary infection rate associated with myelosuppression. Results: Crade Ⅲ and Ⅳ leukopenia occurred in 10 patients (25％) in the experimental group, whereas 18 patients(45％) in the control group. There was a siginificant difference between two groups (P＜0.05). Conclusion: Diyushengbai tablet is an effective drug for treating myelosuppression in patients receiving chemotherapy of improved EOF regimen and deserved to apply popularly in the clinic.